JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KROP, S.
Right arrow Articles by GOLD, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KROP, S.
Right arrow Articles by GOLD, H.
Journal of Pharmacology And Experimental Therapeutics, Vol. 88, Issue 3, 260-267, 1946
Copyright © 1946 by American Society for Pharmacology and Experimental Therapeutics


COMPARATIVE STUDY OF SEVERAL BARBITURATES WITH OBSERVATIONS ON IRREVERSIBLE NEUROLOGICAL DISTURBANCES

STEPHEN KROP 1 and HARRY GOLD 1

1 Department of Pharmacology, Cornell University Medical College, New York, 21, New York

1. The approximate oral LD50 for several barbiturates in the cat were as follows: seconal, 50 mg. per Kg.; pentobarbital, 100; the barbiturate of sigmodal, 110; pernoston, 135; phenobarbital, 175. Attention is called to the extreme individual variation which limits the precision of the LD50 values.

2. The courses of action after oral administration of the approximate LD50 dose in the cat are substantially similar for seconal, pentobarbital, the barbiturate of sigmodal, and pernoston, namely, onset of ataxia in about 5 minutes, maximum narcosis in about 30 minutes, duration of the full effects for about 18 hours, and disappearance of ataxia in 2 to 3 days. The onset in the case of phenobarbital is somewhat slower, and the time for disappearance of ataxia is about 3 times as long.

3. The duration of action of the barbiturate of sigmodal in the dog is somewhat shorter than in the cat.

4. Large doses of secondary amyl-beta-bromallyl barbituric acid (barbiturate of sigmodal) produce an irreversible damage of the central nervous system resulting in motor, postural and reflex abnormalities in about 8 per cent of cats, but not in dogs.

5. Large doses of secondary butyl-beta-bromallyl barbituric acid (pernoston) also possess this action on the central nervous system to some degree in cats.

6. This action on the central nervous system of the cat was not observed with several other compounds free of the bromallyl group, namely, seconal, pentobarbital, and phenobarbital.

7. In view of the species differences, the large doses of the barbiturate which were used to produce these central nervous system effects, and the absence of reports of such effects from their therapeutic use, these observations in the cat may not be applicable to the use of these barbiturates in humans, at least in the range of hypnotic doses.

Submitted on June 3, 1946







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1946 by the American Society for Pharmacology and Experimental Therapeutics.